For Durham-based Tranzyme Pharma, the past year has been successful. Highlights include entering into a broad drug discovery partnership with Bristol-Myers Squibb and, most recently, a licensing agreement with Norgine B.V., a European specialty pharmaceutical company, for the exclusive rights to develop and commercialize Tranzyme’s novel ghrelin agonist, ulimorelin (TZP-101) in Europe, Australia, New Zealand, the Middle... 

After eight years in business, Wilmington Pharmaceuticals is successfully executing a business model that transforms existing drugs into fast disintegrating formulations. They capitalize on off-patent formulations or partnerships with a drug’s original developers.  “Like most entrepreneurial ideas, it started by tossing ideas around with friends in the industry and friends who are financially astute in other industries,”... 

SBTDC- Navigating Capital Resources Capital resources are the biggest challenge to any young company, says Paul Ulanch, director of technology development and commercialization for the Small Business Technology Development Center. Ulanch’s team offers counseling and support mostly to tech companies to help them navigate the options of early stage funding options.  “Clients have business plans, but they are not thought...